Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Context Therapeutics Inc. Director's Dealing 2025

Jun 9, 2025

34269_dirs_2025-06-09_ce582548-0123-4b5a-9a09-0246ed9a21d2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Context Therapeutics Inc. (CNTX)
CIK: 0001842952
Period of Report: 2025-06-09

Reporting Person: Chagin Karen Deborah (Chief Medical Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-06-09 Stock Option (right to buy) $0.703 A 153000 Acquired 2035-06-08 Common Stock (153000) Direct

Footnotes

F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on June 9, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.